367 related articles for article (PubMed ID: 27626685)
41. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
42. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
43. High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
Moiseyenko VM; Dolmatov GD; Moiseyenko FV; Ivantsov AO; Volkov NM; Chubenko VA; Abduloeva NKh; Bogdanov AA; Sokolenko AP; Imyanitov EN
Med Oncol; 2015 Apr; 32(4):89. PubMed ID: 25711630
[TBL] [Abstract][Full Text] [Related]
44. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
[TBL] [Abstract][Full Text] [Related]
45. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
Buckley NE; Haddock P; De Matos Simoes R; Parkes E; Irwin G; Emmert-Streib F; McQuaid S; Kennedy R; Mullan P
Oncotarget; 2016 Apr; 7(15):19884-96. PubMed ID: 26943587
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
47. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
48. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of neoadjuvant cisplatin and oral capecitabine in triple-negative breast cancers: a pilot study.
Tariq K; Rana F; Samiian L; Kilkenny JW; Khan R; Latif N
Clin Adv Hematol Oncol; 2013 May; 11(5):291-5. PubMed ID: 23880712
[TBL] [Abstract][Full Text] [Related]
50. Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Korlimarla A; Prabhu JS; Remacle J; Rajarajan S; Raja U; C E A; Srinath BS; Manjunath S; K S G; Correa M; M S N P; Sridhar TS
PLoS One; 2016; 11(4):e0153113. PubMed ID: 27077368
[TBL] [Abstract][Full Text] [Related]
51. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Agrawal LS; Mayer IA
Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
[TBL] [Abstract][Full Text] [Related]
52. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
Wang D; Feng J; Xu B
Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
[No Abstract] [Full Text] [Related]
53. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
54. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Teraoka S; Sato E; Narui K; Yamada A; Fujita T; Yamada K; Oba M; Ishikawa T
J Surg Res; 2020 Jun; 250():143-147. PubMed ID: 32044511
[TBL] [Abstract][Full Text] [Related]
56. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy.
Wasserman JK; Williams PA; Islam S; Robertson SJ
Pathol Res Pract; 2016 Jun; 212(6):539-44. PubMed ID: 27067807
[TBL] [Abstract][Full Text] [Related]
57. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
59. Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?
Torrisi R; Zuradelli M; Agostinetto E; Masci G; Losurdo A; De Sanctis R; Santoro A
Crit Rev Oncol Hematol; 2019 Mar; 135():66-75. PubMed ID: 30819448
[TBL] [Abstract][Full Text] [Related]
60. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]